Happy Holidays and a Happy New Year from all at Median

  • Leading innovation with purpose
  • Supporting our customers in achieving their goals
  • Committing to quality in all we do
  • Putting the patient first

Harnessing the power of Imaging Phenomics

At Median, we’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

The fight against disease is a joint effort

While our expertise and resources are unique, we don’t work alone. The fight against disease is a joint effort and the spirit of cooperation is found in everything we do. Whether working in clinical trials or patient care and treatment, we share the same single-minded goal. To defeat the diseases that still touch so many lives.

Pushing the boundaries of imaging technology

At Median we’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

CEO’s message


Fredrik Brag talks about how we’re looking to change the game. To transform the landscape in which we work and create a new world of possibilities for biopharma companies and healthcare professionals alike.

Read more

The Imaging Phenomics Company®

Median Technologies is the Imaging Phenomics Company®. Learn about our MediScan® portfolio for Patient Care, our Lesion Management Solution (LMS) technology and iBiopsy®, our Imaging Biomarker Phenotyping System.

Watch

News

14 December 2017

Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials

Press release – For immediate release – 5:45pm CET

Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials – New platform enables high quality, accurate and predictive data for critical imaging endpoints

28 November 2017

Median Technologies inks a collaboration agreement with Memorial Sloan Kettering Cancer Center for a study dealing with prostate cancer

iBiopsy® is a groundbreaking investigational imaging platform developed by Median, enabling the combination between imaging biomarkers and Phenomics. The collaboration supports the expansion of Median’s iBiopsy® to prostate cancer management

21 November 2017

Median Technologies to attend the 103rd Scientific Assembly and Annual Meeting of the RSNA, to be held from November 26 to December 1, 2017 in Chicago, IL, USA

Median will feature its investigational imaging biomarker phenotyping system iBiopsy® and its advanced imaging analysis technology MediScan® at Booth #3203 South Hall A.

17 November 2017

Median Technologies awarded “Listed Company of Région Méditerranée” from Deloitte/In Extenso Technology Fast 50 2017

Median Technologies awarded “Listed Company of Région Méditerranée” from Deloitte/In Extenso Technology Fast 50 2017 – Median is the fastest growing listed company of Région Méditerranée within the last 4 years (2013-2016).

9 November 2017

Median Technologies appoints Dr. Peter Bannister as Chief Technology Officer

As Chief Technology Officer, Dr. Bannister is responsible for leading the development and scientific research teams at Median and ensuring that Median’s products directly address the unmet healthcare needs identified by the company’s clinical end users. Peter Bannister brings more than 15 years of experience developing novel imaging products.

1/5

Opinion

12 October 2017
Different Types of Imaging Criteria: Morphological Measures

Different Types of Imaging Criteria: Morphological Measures

Different Types of Imaging Criteria: Morphological Measures In oncology clinical trials, therapy is generally assessed using imaging response criteria involving imaging biomarkers. Imaging…

11 July 2017
Super Resolution Imaging – For Better Medical Image Analysis

Super Resolution Imaging – For Better Medical Image Analysis

Super Resolution Imaging – For Better Medical Image Analysis If you are fan of science fiction films and you are 40+ like me,…

30 May 2017
Why Cultural Fit Matters when Selecting an Imaging CRO

Why Cultural Fit Matters when Selecting an Imaging CRO

Why Cultural Fit Matters when Selecting an Imaging CRO In the clinical trials process, high quality imaging used as surrogate endpoints significantly improves…

16 May 2017
Minimizing Variability in Imaging Reads for Clinical trials

Minimizing Variability in Imaging Reads for Clinical trials

Minimizing Variability in Imaging Reads for Clinical trials In oncology, response to treatment is typically assessed by measuring tumor size and growth over…

2 May 2017
Putting patient needs first improves engagement – from recruitment to their last medical image.

Putting patient needs first improves engagement – from recruitment to their last medical image.

Putting patient needs first improves patient engagement in a clinical trial, and delivers a better experience for everyone involved – from recruitment to…

1/5
Imaging for patient care

Identifying treatments that work

Imaging biomarkers provide a unique insight into treatment progress at every stage of a disease. In cancer for instance, comprehensive quantitative information plays an invaluable role in defining, tracking and measuring treatment outcomes. Providing clear evidence of what works and what doesn’t.

Read more

Imaging for clinical trials

Advancing treatments of the future

Working with biopharmaceutical companies, and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments

Read more

Ibiopsy®

Powering the phenomics revolution

We’re changing the game; transforming the landscape. We’re capturing the power of big data and unique biomarker imaging technology to create a new world of possibilities for biopharma and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

europe

Median Technologies
Les Deux Arcs, Bât B
1800, route des Crêtes
06560 Valbonne
France

Get in touch

Get in touch





Jobs at Median

United States

Legal address
Median Technologies Inc
C/O Pramex International
1251 Avenue of the Americas
3rd Floor
New York NY 10020

US offices

Median Technologies Inc
300 TradeCenter
Suite 5610
Woburn MA 01801

Cookies help us deliver our services. By using our services, you agree to our use of cookies.